The brazil cardiovascular devices market size was valued at USD 304.36 million in 2025 and estimated to grow from USD 316.5 million in 2026 to reach USD 384.86 million by 2031, at a CAGR of 3.99% during the forecast period (2026-2031). This report is Segmented by Device Type (Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices), by Application (Coronary Artery Disease, Arrhythmia and More), by End User (Hospitals & Cardiac Centers, Ambulatory Surgical Centers and More) and Geography. The Report Offers the Value (in USD Million) for all the Above Segments.
Other drivers and restraints analyzed in the detailed report include:
Brazil Cardiovascular Devices Market Trends and Insights
Rising Prevalence of Coronary Artery Disease in Brazil's Urban Centers
Cardiovascular morbidity is climbing sharply in São Paulo, Rio de Janeiro and other metropolises as the share of residents aged ≥65 heads to 13.6% by 2030. Uneven primary-care performance - worst in the Southeast - pushes more patients toward interventional solutions rather than prevention . Diagnostic cardiac imaging guidelines released in 2024 emphasize CT and MRI as first-line tools, spurring equipment upgrades across referral hospitals [2]. Private health insurers cover over half of specialty consultations, supporting broader access to stents, valves and rhythm devices. Collectively, these factors elevate procedure volumes and reinforce the cardiovascular devices market growth outlook.Privatization-Fueled Growth of Supplementary Health Insurance Plans Boosting Device Affordability
Brazil’s private payer base keeps expanding, helped by hospital consolidation such as the proposed Dasa-Amil merger that would create a 4,500-bed network with USD 2 billion in annual sales. Larger systems negotiate bulk discounts yet also demand newer technology, raising throughput for transcatheter valves and intracardiac monitors. Reimbursement studies show intensive-care tariffs increase in line with provider market share, allowing investors to recoup capital expenditures on high-end devices sooner. Supplementary plans now cover a broader list of cardiovascular interventions approved by ANS in October 2024, widening eligibility for minimally invasive procedures [1]. Greater disposable income among insured urban dwellers accelerates elective uptake, supporting the cardiovascular devices market trajectory through 2030.Lengthy ANVISA Approval Timelines for Novel Cardiovascular Technologies
Device makers navigate multi-step submissions that include Brazilian Good Manufacturing Practice audits, technical dossiers, and in-country representation, adding 30 days just for import authorization on top of dossier review. Even after the recent IN 289/2024 aimed at streamlining certain products, approval lags still contrast with the United States’ 101-day clearance for complex valves. The delay slows first-to-market advantage and can shorten patent-protected sales windows. Hospitals may postpone capital budgets while waiting for registrations, hindering quicker penetration of leadless CRM systems or next-generation ablation catheters. Consequently, the regulatory hurdle subtracts an estimated 1.3 percentage points from the cardiovascular devices market CAGR until reforms gain traction.Other drivers and restraints analyzed in the detailed report include:
- Rapid Adoption of Transcatheter Therapies in Southeast Brazil
- Digital Health Integration Mandates Accelerating Remote Cardiac Monitoring Uptake
- Skilled Electrophysiologist Shortage Constricting Advanced CRM Implant Volumes
Segment Analysis
In 2025 diagnostic and monitoring products captured 57.80% of the cardiovascular devices market size and are advancing at a 6.05% CAGR to 2031, reflecting guideline-driven adoption of cardiac CT and MRI in major centers. Uptake also rides on the rollout of cloud-based ECG platforms that feed AI algorithms for arrhythmia detection. Therapeutic segments grow more slowly yet remain strategic. Cardiac rhythm management benefits from Boston Scientific’s modular leadless system that posted high implant success at ESC 2024, prompting Brazilian electrophysiologists to prepare for broader deployment once ANVISA approves. Transcatheter heart valves represent the fastest unit growth as Medtronic and Abbott channel inventory into urban hubs soon after CE-level clearances medtronic. Investments totaling USD 25.01 billion in rhythm devices worldwide indicate a pipeline of miniaturized implants and ablation tools that will expand the cardiovascular devices industry footprint in Brazil over the medium term.Complete Report Scope:
- By Device Type
- Diagnostic & Monitoring Devices
- ECG Systems
- Remote Cardiac Monitor
- Cardiac MRI
- Cardiac CT
- Echocardiography / Ultrasound
- Fractional Flow Reserve (FFR) Systems
- Therapeutic & Surgical Devices
- Coronary Stents
- Drug-Eluting Stents
- Bare-Metal Stents
- Bioresorbable Stents
- Catheters
- PTCA Balloon Catheters
- IVUS/OCT Catheters
- Cardiac Rhythm Management
- Pacemakers
- Implantable Cardioverter Defibrillators
- Cardiac Resynchronization Therapy Devices
- Heart Valves
- TAVR/TAVI
- Mechanical Valves
- Tissue/Bioprosthetic Valves
- Ventricular Assist Devices
- Artificial Hearts
- Grafts & Patches
- Other Cardiovascular Surgical Devices
- Coronary Stents
- Diagnostic & Monitoring Devices
- By Application
- Coronary Artery Disease
- Arrhythmia
- Heart Failure
- Structural Heart Disease
- Hypertension
- Others
- By End-User
- Hospitals & Cardiac Centers
- Home-Care Settings
- Ambulatory Surgical Centers
List of Companies Covered in this Report:
- Medtronic
- Abbott Laboratories
- Boston Scientific
- Edwards Lifesciences Corp.
- Johnson & Johnson (Biosense Webster/Cordis)
- MicroPort Scientific Corp.
- Terumo Corp.
- LivaNova
- BIOTRONIK
- GE HealthCare Technologies Inc.
- Koninklijke Philips
- Siemens Healthineers
- W. L. Gore & Associates
- Getinge AB (Maquet)
- AngioDynamics
- Penumbra
- Shockwave Medical Inc.
- LivaNova
- Cardioline S.p.A.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value)
6 Competitive Landscape
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Medtronic plc
- Abbott Laboratories
- Boston Scientific Corp.
- Edwards Lifesciences Corp.
- Johnson & Johnson (Biosense Webster/Cordis)
- MicroPort Scientific Corp.
- Terumo Corp.
- LivaNova PLC
- BIOTRONIK SE & Co. KG
- GE HealthCare Technologies Inc.
- Koninklijke Philips N.V.
- Siemens Healthineers AG
- W. L. Gore & Associates
- Getinge AB (Maquet)
- AngioDynamics Inc.
- Penumbra Inc.
- Shockwave Medical Inc.
- Livanova PLC
- Cardioline S.p.A.
